{
  "abstract": "We agree with Sun’s central assertion: glucagon-like peptide-1 (GLP-1) receptor agonists are not “magic bullets” for the treatment of obesity.12 West and colleagues’ meta-analysis showed that discontinuation of pharmacotherapy often leads to weight regain, particularly when it has not been paired with structured behavioural interventions.3 Rather than viewing this as a pharmacological failure, we think it reflects a deeper need to embed such agents into systems that prioritise durable behaviour change.",
  "authors": [
    {
      "affiliations": [
        "Department of Diabetes and Metabolic Diseases, University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan"
      ],
      "name": "Kengo Miyoshi"
    },
    {
      "affiliations": [
        "Department of Diabetes and Metabolic Diseases, University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan"
      ],
      "name": "Yoshitaka Sakurai"
    },
    {
      "affiliations": [
        "Department of Diabetes and Metabolic Diseases, University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan"
      ],
      "name": "Toshimasa Yamauchi"
    }
  ],
  "title": "Pharmacotherapy as a catalyst for behaviour change",
  "uid": "f60076ee-796b-5ef9-aa7c-18447897e840"
}